Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drugs

• Publication date

  2016-01-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40265-015-0526-3PMID 26729187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients

  2016cited by this paper
• [Venous thromboembolism in multiple myeloma].

  2016cited by this paper
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

  2016cited by this paper
• Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.

  2015cited by this paper
• Edoxaban for treatment of venous thromboembolism in patients with cancer

  2015cited by this paper
• Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.

  2015cited by this paper
• Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.

  2015influential reference
• Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients.

  2015cited by this paper
• Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.

  2015influential reference
• Venous thrombosis and cancer: from mouse models to clinical trials

  2015cited by this paper
• Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.

  2015cited by this paper
• Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry.

  2015cited by this paper
• Is risk-benefit of warfarin for atrial fibrillation with heart failure determined by heart failure severity?

  2015cited by this paper
• Nonleg Venous Thrombosis in Critically Ill Adults

  2015influential reference
• Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.

  2015cited by this paper
• Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study

  2015cited by this paper
• 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.

  2014cited by this paper
• Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants.

  2014cited by this paper
• How I treat splanchnic vein thrombosis.

  2014influential reference
• Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study.

  2014cited by this paper
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

  2014cited by this paper
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

  2014cited by this paper
• ESC Guidelines on the diagnosis and management of acute pulmonary embolism

  2014cited by this paper
• Cancer-associated unsuspected pulmonary embolism.

  2014cited by this paper
• Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.

  2014cited by this paper
• Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer.

  2014cited by this paper
• Bleeding complications during anticoagulant treatment in patients with cancer.

  2014cited by this paper
• Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.

  2014cited by this paper
• Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.

  2014cited by this paper
• Venous Thromboembolism in Multiple Myeloma

  2014cited by this paper
• Management of challenging cases of patients with cancer‐associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH

  2013cited by this paper
• Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

  2013cited by this paper
• Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

  2013influential reference
• A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism

  2013cited by this paper
• Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry.

  2013cited by this paper
• Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

  2013cited by this paper
• Procoagulants for management of bleeding with the new oral anticoagulants

  2013cited by this paper
• Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism.

  2013cited by this paper
• CANCER-ASSOCIATED THROMBOTIC DISEASE Epidemiology of cancer-associated venous thrombosis

  2013cited by this paper
• Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases.

  2013cited by this paper
• Epidemiology of cancer-associated venous thrombosis.

  2013cited by this paper
• Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE

  2013cited by this paper
• Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study)

  2013cited by this paper
• Anticoagulant therapy in patients with non‐cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding

  2013cited by this paper
• Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case‐control study

  2012cited by this paper
• Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer

  2012cited by this paper
• Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

  2012influential reference
• Diagnosis and management of upper extremity deep-vein thrombosis in adults

  2012cited by this paper
• Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

  2012cited by this paper
• Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

  2012cited by this paper
• Venous thromboembolism in cancer patients – Risk scores and recent randomised controlled trials

  2012cited by this paper
• Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

  2012cited by this paper
• Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Unsuspected pulmonary embolism in patients with cancer.

  2012cited by this paper
• A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer

  2012cited by this paper
• Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism.

  2012cited by this paper
• Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

  2011cited by this paper
• Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

  2011cited by this paper
• Predictive and associative models to identify hospitalized medical patients at risk for VTE.

  2011cited by this paper
• Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer

  2011cited by this paper
• Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.

  2011cited by this paper
• Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients.

  2011cited by this paper
• Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.

  2011cited by this paper
• Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning

  2011cited by this paper
• A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score

  2010cited by this paper
• Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging.

  2010cited by this paper
• Survival and recurrence in patients with splanchnic vein thromboses.

  2010cited by this paper
• Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: A subgroup analysis of the Van Gogh DVT trial

  2010cited by this paper
• PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma

  2010cited by this paper
• Unsuspected pulmonary embolism

  2010cited by this paper
• Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study

  2010cited by this paper
• Clinical outcomes in patients with isolated subsegmental pulmonary emboli diagnosed by multidetector CT pulmonary angiography.

  2010cited by this paper
• Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study.

  2010influential reference
• Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow‐up study

  2010cited by this paper
• Unsuspected Pulmonary Emboli in Oncology Patients Undergoing Routine Computed Tomography Imaging

  2010cited by this paper
• Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy.

  2010cited by this paper
• Prediction of venous thromboembolism in cancer patients.

  2010cited by this paper
• A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.

  2009cited by this paper
• Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis

  2009cited by this paper
• Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials

  2009cited by this paper
• Prevention of venous thromboembolism in hospitalized patients with cancer.

  2009cited by this paper
• Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

  2009cited by this paper
• Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.

  2008cited by this paper
• Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).

  2008cited by this paper
• Thromboprophylaxis for patients with cancer and central venous catheters

  2008cited by this paper
• Extended perioperative thromboprophylaxis in patients with cancer

  2008cited by this paper
• Prognostic Factors in Noncirrhotic Patients With Splanchnic Vein Thromboses

  2007cited by this paper
• A pilot study of central venous catheter survival in cancer patients using low‐molecular‐weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)

  2007cited by this paper
• Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery

  2007cited by this paper
• Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

  2007cited by this paper
• Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

  2006cited by this paper
• Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history.

  2006cited by this paper
• Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer.

  2006cited by this paper
• Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.

  2006cited by this paper
• Incidental detection of pulmonary emboli on routine MDCT of the chest.

  2005cited by this paper
• The causes and consequences of cancer-associated malnutrition.

  2005cited by this paper
• Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.

  2005cited by this paper
• Electronic alerts to prevent venous thromboembolism among hospitalized patients.

  2005cited by this paper

• Prediction of Bleeding in Patients being Considered for Venous Thromboembolism Prophylaxis.

  2023cites this paper
• Comparison of the Effects of Fucoidans on the Cell Viability of Tumor and Non-Tumor Cell Lines

  2019influential citation
• Upper Extremity Deep Vein Thrombosis

  2018cites this paper
• Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study

  2018cites this paper
• Thrombodynamics—A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment

  2018cites this paper
• Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.

  2017cites this paper
• Catheter Related Problems in Pediatric Oncology Treatment

  2016cites this paper